Ignite Creation Date:
2025-12-24 @ 1:31 PM
Ignite Modification Date:
2026-04-07 @ 6:47 PM
Study NCT ID:
NCT02732795
Status:
COMPLETED
Last Update Posted:
2019-09-09
First Post:
2016-02-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sleep Apnea and Obesity Affects on Morphine Pharmacokinetics
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 43}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-09', 'completionDateStruct': {'date': '2018-09-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-09-05', 'studyFirstSubmitDate': '2016-02-04', 'studyFirstSubmitQcDate': '2016-04-04', 'lastUpdatePostDateStruct': {'date': '2019-09-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-04-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-09-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plasma Morphine Area Under the Curve (AUC)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine AUC due to obesity and OSAS'}, {'measure': 'Maximum Plasma Morphine Concentration (Cmax)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine Cmax due to obesity and OSAS'}, {'measure': 'Time to Maximum Plasma Morphine Concentration (Tmax)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine Tmax due to obesity and OSAS'}, {'measure': 'Half Life of Plasma Morphine Concentration (T1/2)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine T1/2 due to obesity and OSAS'}, {'measure': 'Plasma Morphine Clearance (Cl)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine Cl due to obesity and OSAS'}, {'measure': 'Plasma Morphine Volume of Distribution (Vd)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in morphine Vd due to obesity and OSAS'}, {'measure': 'Plasma Morphine 3-glucuronide (M3G) Maximum Plasma Concentration (Cmax)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in M3G Cmax due to obesity and OSAS'}, {'measure': 'Time to Maximum Morphine 3-glucuronide (M3G) Concentration (Tmax)', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in M3G Tmax due to obesity and OSAS'}, {'measure': 'Morphine 3-glucuronide (M3G) to Morphine ratio', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in metabolism of morphine due to obesity and OSAS'}, {'measure': 'Morphine 3-glucuronide (M3G) to Morphine 6-glucuronide (M6G) ratio', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine changes in metabolism of morphine due to obesity and OSAS'}], 'secondaryOutcomes': [{'measure': 'Biomarker concentrations', 'timeFrame': 'Through study completion, up to 24 hours after study initiation', 'description': 'To determine whether inflammatory biomarkers correlate to the severity of sleep apnea. Biomarkers that will be studied include IL 1,6,10, CRP, TNF-alpha, leptin, and insulin.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Pediatric Sleep Apnea', 'Obesity', 'Morphine Metabolism']}, 'descriptionModule': {'briefSummary': 'Adenotonsillectomy (AT) is one of the most common pediatric surgeries performed, and is estimated to comprise 530,000 procedures in children under 15 years of age. Historically, the leading cause for these procedures was recurrent infections; however, more recently surgical indications include sleep disordered breathing and obstructive sleep apnea (OSAS). Pre-operative polysomnography (PSG) is recommended for all children with suspected OSAS prior to undergoing AT, although it is unclear whether sleep disordered breathing characteristics predict post-operative outcomes or complications.\n\nObesity has become an epidemic in the pediatric population. More recently, an increased population of obese children are presenting for AT with upper airway obstruction with or without tonsillar hypertrophy, which is similar to the adult etiology of OSAS. Obesity is a multisystem disease, causing fatty liver and cardiac disease, defects in glucose metabolism, insulin resistance, leptin resistance, and creates a state of chronic inflammation. Markers for inflammation, including tumor necrosis factor (TNF)-α, C-reactive protein (CRP), leptin, interleukin (IL)-6 and IL-10, are abnormal in obese patients and have also been linked to more severe OSAS disease in children even after controlling for BMI.\n\nIn pediatrics, medication dosing is based on an actual body-weight calculation, however, recent reports suggest that this dosing method is over-dosing patients with obesity. Therefore, increased respiratory complications after surgery may be related to inappropriate intra-operative opioid dosing.\n\nSpecific Aim 1 (SA1): To compare morphine pharmacokinetics in normal children \\<=12 years of age, non-obese children with severe OSAS, and obese children with severe OSAS. The investigators hypothesize that obesity independently enhances morphine pharmacokinetics.\n\nSpecific Aim 2 (SA2): To determine whether biomarkers related to obesity, chronic inflammation, and OSAS predict changes to morphine pharmacokinetics. The investigators hypothesize that inflammatory and obesity-related biomarkers are elevated in overweight children with OSAS, more so in obese children with OSA, compared to lean children with OSAS. In addition, the investigators hypothesizes that leptin independently is linked to altered morphine pharmacokinetics.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '12 Years', 'minimumAge': '5 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Child presenting for surgery that will require opioids\n* Age between 5 -12 years of age\n\nOSAS group:\n\n* Pre-operative polysomnography study conducted prior to day of surgery\n\nObese:\n\n* Body weight \\>95th percentile for age.\n\nExclusion Criteria:\n\n* Emergency procedures involving AT, including tonsillar bleeding\n* Patients allergic to morphine\n* Patients with comorbidities altering opioid metabolism (i.e. liver disease)\n* Patients with chronic inflammatory, rheumatologic, or other confounding co-morbid diseases (i.e. Crohns disease, ulcerative colitis, sickle cell, Sjogren's, etc.)"}, 'identificationModule': {'nctId': 'NCT02732795', 'briefTitle': 'Sleep Apnea and Obesity Affects on Morphine Pharmacokinetics', 'organization': {'class': 'OTHER', 'fullName': 'Johns Hopkins University'}, 'officialTitle': 'Effects of Obstructive Sleep Apnea Syndrome and Obesity on Morphine Pharmacokinetics in Children', 'orgStudyIdInfo': {'id': 'IRB00034512'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Morphine dosing', 'description': 'Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.', 'interventionNames': ['Other: Morphine pharmacokinetic evaluation']}], 'interventions': [{'name': 'Morphine pharmacokinetic evaluation', 'type': 'OTHER', 'description': 'Each group received morphine and blood drawn to evaluate morphine PK', 'armGroupLabels': ['Morphine dosing']}]}, 'contactsLocationsModule': {'locations': [{'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': "Bloomberg Children's Hospital", 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Johns Hopkins University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}